Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders-Reference-Cited by-同舟云学术

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

Published:2010-10 Issue:2 Volume:225 Page:384-390
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Hodgson Robert A.,Bedard Paul J.,Varty Geoffrey B.,Kazdoba Tatiana M.,Di Paolo Therese,Grzelak Michael E.,Pond Annamarie J.,HadjTahar Abdallah,Belanger Nancy,Gregoire Laurent,Dare Aurelie,Neustadt Bernard R.,Stamford Andrew W.,Hunter John C.

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference42 articles.

1. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys;Arai;J. Neural Transm. Park Dis. Demen. Sect.,1995

2. Combined effects of cabergoline and l-Dopa on parkinsonism in MPTP-treated cynomolgus monkeys;Arai;J. Neural Transm.,1996

3. Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding;Bedard;Brain Res.,1986

4. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD;Bibbiani;Exp. Neurol.,2003

5. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias;Calon;Brain,2004

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms;Neurological Sciences;2024-02-23

2. The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets;Journal of Pharmacological Sciences;2023-07

3. Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach;Molecular Neurobiology;2023-06-30

4. Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia;Neuropharmacology;2023-03

5. How and why the adenosine A2A receptor became a target for Parkinson’s disease therapy;International Review of Neurobiology;2023